NCT04156178 is a EARLY_PHASE1 clinical trial of CD20-CD19 cCAR T cells in B Cell Lymphoma, sponsored by iCell Gene Therapeutics.

Who is sponsoring NCT04156178?

NCT04156178 is sponsored by iCell Gene Therapeutics.

What drugs are being tested in NCT04156178?

Interventions in NCT04156178: CD20-CD19 cCAR T cells.

What condition does NCT04156178 study?

NCT04156178 studies B Cell Lymphoma, B Cell Leukemia.

Is NCT04156178 still recruiting?

NCT04156178 is currently status unknown. Last updated 12 November 2019.

Last reviewed 2019-11-12 · How we verify

NCT04156178

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Status unknown EARLY_PHASE1 Last updated 12 November 2019

What this trial tests

EARLY_PHASE1 trial testing CD20-CD19 cCAR T cells in B Cell Lymphoma in 12 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	iCell Gene Therapeutics
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 August 2018
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	2 locations across China

Drugs / interventions tested

CD20-CD19 cCAR T cells — full drug profile →

Conditions studied

B Cell Lymphoma — all drugs for B Cell Lymphoma →
B Cell Leukemia — all drugs for B Cell Leukemia →

Sponsor

iCell Gene Therapeutics — full company profile →

Who can join

Eligibility, any sex, with B Cell Lymphoma or B Cell Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V, Perutelli F, Salvetti C, Boccellato E, et al · · 2020 · cited 54× · PMID 33312177 · DOI 10.3389/fimmu.2020.594556
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
Cassioli C, Patrussi L, Valitutti S, Baldari CT. · · 2022 · cited 17× · PMID 36430728 · DOI 10.3390/ijms232214255

Verify or expand the search:

Other recruiting trials for B Cell Lymphoma

Currently open trials in the same condition.

NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT06976437 — A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors · EARLY_PHASE1 · recruiting
NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
NCT06742996 — A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Phase 3 · recruiting

Other iCell Gene Therapeutics trials

Trials by the same sponsor.

NCT05212584 — CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma · Phase 1 · unknown
NCT05445765 — Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia · Phase 1 · unknown
NCT05474885 — BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · unknown
NCT04934774 — Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances · Phase 1 · unknown
NCT04594135 — Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iCell Gene Therapeutics
Last refreshed: 12 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing